Drug class
Topical/systemic pleuromutilin-related antibacterial; bacterial protein-synthesis inhibitor (historical)
Mechanism of action
Interferes with bacterial protein synthesis by binding to the 50S ribosomal subunit and inhibiting peptide-chain formation. Clinical antibacterial activity and spectrum depend on the product and local susceptibility.
General use cases
- Historically used in selected respiratory tract infections caused by susceptible Gram-positive bacteria in countries where clofoctol was authorised; current marketed status and role are limited
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
